These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34989825)

  • 21. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies.
    Schmidt N; Hess V; Zumbrunn T; Rothermundt C; Bongartz G; Potthast S
    Eur Radiol; 2013 Mar; 23(3):632-9. PubMed ID: 22918564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
    Goebel J; Hoischen J; Gramsch C; Schemuth HP; Hoffmann AC; Umutlu L; Nassenstein K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2527-2533. PubMed ID: 28825135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
    Chen LF; Fu GZ; Huang DP; Man Y; Jin Y; Dong QT; Huang YB; Chen YC; Wang HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct; 22(10):977-983. PubMed ID: 31630497
    [No Abstract]   [Full Text] [Related]  

  • 26. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
    de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP
    J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
    Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
    Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
    Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
    AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiological evaluation of response in patients with locally advanced/metastatic soft tissue sarcoma treated with trabectedin.
    Ceddia S; Onesti CE; Vari S; Torchia A; Cosimati A; Riva F; Maccallini MT; Cerro M; Benvenuti G; Russillo M; Anelli V; Sperduti I; Biagini R; Ferraresi V
    Front Pharmacol; 2024; 15():1411707. PubMed ID: 39228518
    [No Abstract]   [Full Text] [Related]  

  • 33. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
    Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy.
    Kwon T; Lee JL; Kim JK; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1751-8. PubMed ID: 24841738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. We should desist using RECIST, at least in GIST.
    Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
    J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
    Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
    Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma.
    Reijers SJM; Gennaro N; Bruining A; van Boven H; Snaebjornsson P; Bekers EM; van Coevorden F; Scholten AN; Schrage Y; van der Graaf WTA; Haas RLM; van Houdt WJ
    Acta Oncol; 2023 Jan; 62(1):25-32. PubMed ID: 36637511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
    Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab.
    Xu Y; Yang Y; Li L; Zhou A; Zhang H; Ye F; Zhang W; Zhao H; Zhao X
    Front Oncol; 2022; 12():848129. PubMed ID: 35515116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.